The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
about
Clozapine: a review of clinical practice guidelines and prescribing trendsAtypical antipsychotics for psychosis in adolescentsAtypical antipsychotics for psychosis in adolescentsInterventions for smoking cessation and reduction in individuals with schizophreniaImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaPharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature reviewProfile of blonanserin for the treatment of schizophreniaDownregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.Early interventions in risk groups for schizophrenia: what are we waiting for?Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeBridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practiceDeveloping psychosis and its risk states through the lens of schizotypy.Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?Augmentation with antidepressants in schizophrenia treatment: benefit or riskCurrent approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatmentsThe treatment of hallucinations in schizophrenia spectrum disordersCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewProphylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant miceOff-label use of sodium valproate for schizophreniaExcess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.Auditory verbal hallucinations as atypical inner speech monitoring, and the potential of neurostimulation as a treatment optionPerception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophreniaThe Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.Effectiveness of switching from antipsychotic polypharmacy to monotherapy.Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP studyVirtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance.Development and usability testing of FOCUS: a smartphone system for self-management of schizophrenia.Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy.Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria.Polypharmacy for schizophrenia.Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic ReviewComparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population.The risk of suicide after clozapine discontinuation: Cause for concern.Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Negative symptoms in schizophrenia.Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trialDisparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis.
P2860
Q21260307-52D19D59-4E9C-4053-B477-4FC2E9E270C0Q24197475-61743830-2B85-4E85-BBFB-DF707297FD23Q24203954-82A9964E-9AE6-4C1D-B8CB-F40A50F2C363Q24235017-2A777216-9DCD-4861-A05A-BB5EDDB0311FQ24597701-0F276304-9261-41FC-90D0-466C26CB0B61Q24598636-A77510A2-F7F6-4863-A3F7-CC406000B64BQ24614169-C6D08297-839C-4106-A429-4B24D6887079Q24631189-EF8F902A-5BE6-407B-861A-74D393B64A01Q26747545-1A458BE8-43A0-464B-A0B7-71D68AA6FEFAQ26752965-80703B0B-1F21-4579-81E0-C219732EE375Q26800235-F5694A52-AB40-4473-8A01-AA36D7204547Q26822553-BFC1FA61-45BD-4052-88EE-E9CD023D5621Q26824270-DADD4D1B-8D0E-4731-B29A-DE4148EF85FCQ26851841-FDAAE8D5-92D8-4D00-85B6-E4706B5E2576Q27003099-CA9F52C5-C1C4-4AA1-8672-02F492B39BD6Q27025380-306A3A73-DD3D-43DD-8679-C766FB212C64Q28079821-04E3F3E8-9ADF-450B-BD9D-AEAC3EF96558Q28484428-2B5292B2-F23F-4954-A302-C66141F6B8E5Q28541404-0A2FF6A0-9866-4781-B411-589CF3011D70Q30379171-9980BCE3-A806-4FDB-A7A1-618C3963FB1DQ30445539-87CE5F58-D78A-4D2C-AD36-D7E8C55AD04BQ30455113-3882D875-8E23-45DC-86EF-5EA9CD77666DQ30492614-AA881246-4411-4038-BF09-3BE1109831E9Q30542484-ABE9B639-47EF-46D6-8972-6A8BD2D1A94BQ30542486-9E225AA9-B2F9-498C-8B9C-EAE7CCA00357Q30627430-69A78E21-E8CF-4BA4-9D01-BB3C138BDF65Q30840149-E7BA4FCC-DCEC-4D85-A9E2-7EF45BBB7A10Q33439993-35E4B960-649A-40BA-990B-1686D075F55AQ33455799-3FBD0A35-0C46-4832-8284-19AAD9DD7569Q33584343-60E8C3FD-693B-4FC9-B2B5-314E50E81E6AQ33634660-AD7018E8-1666-4B15-8801-88EEFF914068Q33695789-E7743B7A-9C53-4DAE-AA81-D2BE7ECA6C02Q33713759-33CC7F0A-9179-4DEC-AF87-085169B608E2Q33796327-6E3AD55B-4DFA-4845-BC20-5A70D1127A26Q33802918-86691B77-55BB-4436-B298-90A23D29F94DQ33820512-5E39FA3C-2BDB-4DF4-BAB4-9E93DB728EC6Q33882729-12C28742-A4D3-42FC-9E8A-800B1C5F23FAQ33914295-858CD76F-3C13-4C9D-90CB-FB1D358B503FQ33953271-2BA6E571-98B5-42BF-9CB1-0FD5D8271C9BQ34022882-20D279CA-8C25-4088-9175-4AECEF155B88
P2860
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The 2009 schizophrenia PORT ps ...... dations and summary statements
@ast
The 2009 schizophrenia PORT ps ...... dations and summary statements
@en
The 2009 schizophrenia PORT ps ...... ations and summary statements.
@nl
type
label
The 2009 schizophrenia PORT ps ...... dations and summary statements
@ast
The 2009 schizophrenia PORT ps ...... dations and summary statements
@en
The 2009 schizophrenia PORT ps ...... ations and summary statements.
@nl
prefLabel
The 2009 schizophrenia PORT ps ...... dations and summary statements
@ast
The 2009 schizophrenia PORT ps ...... dations and summary statements
@en
The 2009 schizophrenia PORT ps ...... ations and summary statements.
@nl
P2093
P2860
P356
P1476
The 2009 schizophrenia PORT ps ...... dations and summary statements
@en
P2093
Bernard A Fischer
Beverly Fang
Deanna L Kelly
Douglas L Boggs
Eunice Peterson
Jason M Noel
Julie Kreyenbuhl
Patrick R Aquino
Robert W Buchanan
Schizophrenia Patient Outcomes Research Team (PORT)
P2860
P356
10.1093/SCHBUL/SBP116
P407
P577
2009-12-02T00:00:00Z